Experience

• Collaborations and Licensing Transactions

  • Voyager Therapeutics in its strategic collaboration agreement with Neurocrine Biosciences to advance multiple gene therapies for the treatment of neurological diseases;
  • Novo Nordisk in its strategic collaboration with Flagship Pioneering to create a portfolio of transformational medicines;
  • an antibody services and technology provider in library development agreements with various partners, including AstraZeneca, Scholar Rock and Biogen;
  • a pharmaceutical company focused on treatments for iron deficiency anemia in adult patients in connection with a license and commercialization agreement with Norgine;
  • Autobahn Labs in its strategic drug discovery collaborations with the Universities of California Los Angeles, San Francisco and San Diego;
  • Editas Medicine in the buildout of its outlicensing strategy and execution, as well as in the renegotiation of its collaboration agreement with Celgene and its strategic alliance and option agreement with Allergan;
  • EQRx in its global strategic partnership with CStone Pharmaceuticals;
  • MacroGenics in its collaboration with I-Mab;
  • Repare Therapeutics in its global research collaboration with Bristol Myers Squibb;
  • Spark Therapeutics in its synthetic vaccine particle licensing transaction with Selecta Biosciences, and in its licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational Luxturna outside the United States; and
  • Voyager Therapeutics in its restructured gene therapy relationship with Sanofi Genzyme, and various collaboration agreements with strategic partners, including Neurocrine Biosciences and AbbVie.